Protocol No.: R3767-ONC-22122

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab In Participants with Unresectable or Metastatic Melanoma
Principal Investigator
Kolodney, Joanna
Phase
III
Age Group
Adult
Applicable Disease Site
Melanoma and Other Skin Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Meg Zafiris
Research Specialist

View on ClinicalTrials.gov